Chondrosarcoma Market

Emerging therapies for Chondrosarcoma, including INBRX-109, TIBSOVO (ivosidenib), and others, are anticipated to drive growth in the Chondrosarcoma market in the coming years.

DelveInsight has launched a new report on “Chondrosarcoma – Market Insights, Epidemiology, and Market Forecast-2034” that delivers an in-depth understanding of the Chondrosarcoma, historical and forecasted epidemiology as well as the Chondrosarcoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Download our sample report @ https://www.delveinsight.com/report-store/chondrosarcoma-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr

Some of the key facts of the Chondrosarcoma Market Report:

• In 2023, approximately 2,300 new cases of chondrosarcoma were reported across the 7MM (U.S., EU5, and Japan). Chondrosarcoma, a type of bone cancer, is categorized into four grades (I–IV), with Grade II being the most common. It primarily affects adults and ranks as the second most frequent primary bone tumor after osteogenic sarcoma.

• At present, there are no approved therapies specifically for chondrosarcoma. This creates a strong market opportunity for the development of targeted molecular therapies and immunotherapies aimed at improving clinical outcomes and reducing recurrence rates in patients with advanced disease.

• Surgery remains the cornerstone of treatment, while radiotherapy and chemotherapy are also utilized. However, due to resistance to these conventional approaches, surgical resection often remains the only effective option for both primary and recurrent chondrosarcoma, posing a major therapeutic challenge.

• Conventional chondrosarcoma, the most prevalent form, responds poorly to chemo and radiation therapies. New treatments targeting IDH mutations—present in about 65% of cases—offer significant potential for innovation in this space.

• Recent updates from the NCCN have added ivosidenib as a treatment for IDH1-mutated conventional or dedifferentiated chondrosarcoma. Additionally, ESMO’s 2021 clinical guidelines support trabectedin as a possible therapy for mesenchymal chondrosarcoma.

• Among the emerging therapies, INBRX-109 stands out as a promising option for patients with unresectable conventional chondrosarcoma, offering potential benefits in progression-free survival along with a favorable safety profile.

• Conventional chondrosarcoma accounts for roughly 80% of all cases. In the U.S., the chondrosarcoma market was valued at around USD 8.5 million in 2023 and is projected to grow steadily through the 2024–2034 forecast period.

• Numerous biopharmaceutical companies are actively advancing drug candidates for chondrosarcoma, including Aadi Bioscience, Acrotech Biopharma, ADC Therapeutics, Advenchen Laboratories, Alkermes, Astex Pharmaceuticals, Atlanthera, Bayer, BioAtla, BioMed Valley Discoveries, Bristol-Myers Squibb, Chia Tai Tianqing, Eli Lilly, ENB Therapeutics, Epizyme, Horizon Therapeutics, Incyte, Inhibrx, Iovance Biotherapeutics, Jiangsu Hengrui Medicine, Karyopharm Therapeutics, Servier, Merck, Nanode Therapeutics, Nerviano Medical Sciences, NKGen Biotech, Novartis, Oncorus, Ono Pharmaceutical, Pfizer, PharmaMar, Rigel Pharmaceuticals, Shanghai Affinity Biomedical Technology, Shanghai De Novo Pharmatech, Taiho Pharmaceutical, and others.

• Pipeline therapies showing strong potential include INBRX-109, TIBSOVO (ivosidenib), and several additional candidates currently under investigation.

Key benefits of the Chondrosarcoma market report:

1. Chondrosarcoma market report covers a descriptive overview and comprehensive insight of the Chondrosarcoma Epidemiology and Chondrosarcoma market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)

2. The Chondrosarcoma market report provides insights on the current and emerging therapies.

3. Chondrosarcoma market report provides a global historical and forecasted market covering drug outreach in 7MM.

4. The Chondrosarcoma market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Chondrosarcoma market.

Got queries? Click here to know more about the Chondrosarcoma Market Landscape

Chondrosarcoma Overview

Chondrosarcoma refers to a group of locally aggressive or malignant tumors that produce a cartilaginous matrix and display a wide range of morphological features and clinical behaviors. These tumors typically originate in bones that develop through endochondral ossification, making chondrosarcoma the most common type of bone sarcoma in individuals over the age of 20. It predominantly affects adults in their 40s to 60s, with the pelvis being the most frequently involved site, followed by the femur, humerus, and ribs. The histologic grade of the tumor is the most critical factor in determining prognosis.

Diagnosing chondrosarcoma involves a comprehensive approach, beginning with a thorough review of the patient’s medical history and a physical examination to identify symptoms and clinical signs. Imaging techniques such as X-rays, CT scans, and MRIs are used to assess the tumor’s size, location, and spread. If chondrosarcoma is suspected, a biopsy is performed to collect tissue for microscopic evaluation by a pathologist, which confirms the diagnosis. The tumor is then graded on a scale from I to IV based on its microscopic characteristics, providing insight into its aggressiveness and likely clinical behavior. Additional staging tests may be conducted to determine whether the cancer has spread to other parts of the body.

Chondrosarcoma Treatment Market

The grade of malignancy and the specific subtype of chondrosarcoma are key factors in determining both the treatment strategy and the patient’s prognosis. Surgery remains the primary and most effective curative option for all subtypes. For intermediate- and high-grade tumors, Enneking’s surgical principles advocate for wide compartmental resection, which offers strong local and systemic tumor control. In contrast, low-grade chondrosarcomas may be effectively managed with intralesional or marginal resection.

Conventional chondrosarcomas typically show poor response to standard chemotherapy and radiotherapy. However, in cases of dedifferentiated chondrosarcoma, neoadjuvant or adjuvant chemotherapy may provide a survival advantage. Treatment often involves a combination regimen using agents such as doxorubicin with cisplatin or ifosfamide.

To know more about the chondrosarcoma treatment algorithms

Chondrosarcoma Market Outlook

The current approach to managing chondrosarcoma is guided by the tumor’s type, grade, and location, with the grading scale (I to III) being the most reliable indicator of clinical behavior. Surgery remains the cornerstone of treatment, as chemotherapy and radiotherapy have shown limited effectiveness. Surgical options include curettage, radical resection, and amputation, with the choice determined by tumor size, anatomical site, and degree of malignancy.

One of the key obstacles in estimating revenue from systemic therapies for chondrosarcoma is the limited effectiveness of chemotherapy, especially for conventional chondrosarcoma. Unlike many other solid tumors, there is no established standard systemic treatment for advanced cases. Several factors contribute to chemotherapy resistance, including the tumor’s slow cell proliferation, expression of the multidrug-resistance gene MDR1 (which produces P-glycoprotein and reduces doxorubicin efficacy), heightened activity of anti-apoptotic and survival pathways (such as increased BCL-2 family protein expression), and poor vascularity due to extensive extracellular matrix, which limits drug penetration.

Additionally, the rarity of chondrosarcoma poses challenges for conducting large-scale randomized clinical trials to assess systemic treatments. While chemotherapy regimens based on osteosarcoma and Ewing sarcoma—such as combinations of cisplatin and doxorubicin—are sometimes used, their success is limited. Other drug combinations, including Gemcitabine, Ifosfamide, Dasatinib, and Pazopanib, have been tested, particularly in dedifferentiated and metastatic cases, but with modest outcomes.

Companies like Inhibrx and Servier are at the forefront of developing new therapies for chondrosarcoma and are currently advancing their lead candidates through various clinical trial phases.

Know more about the rising chondrosarcoma market

Emerging Chondrosarcoma Drugs

• INBRX-109: Inhibrx

• TIBSOVO (ivosidenib): Servier

Scope of the Chondrosarcoma Market Report

• Study Period: 2020-2034

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Chondrosarcoma Companies: Aadi Bioscience Inc, Acrotech Biopharma LLC, ADC Therapeutics SA, Advenchen Laboratories LLC, Alkermes Plc, Astex Pharmaceuticals Inc, Atlanthera, Bayer AG, BioAtla Inc, BioMed, Valley Discoveries Inc, Bristol-Myers Squibb Co, Chia Tai Tianqing Pharmaceutical Group Co Ltd, Eli Lilly and Co, ENB Therapeutics LLC, Epizyme Inc, Horizon Therapeutics Plc, Incyte Corp, Inhibrx Inc, Iovance Biotherapeutics Inc, Jiangsu Hengrui Medicine Co Ltd, Karyopharm Therapeutics Inc, Les Laboratoires Servier SAS, Merck & Co Inc, Nanode Therapeutics Inc, Nerviano Medical Sciences SRL, NKGen Biotech Inc, Novartis AG, Oncorus Inc, Ono Pharmaceutical Co Ltd, Pfizer Inc, Pharma Mar SA, Rigel Pharmaceuticals Inc, Shanghai Affinity Biomedical Technology Co Ltd, Shanghai De Novo Pharmatech Co Ltd, Taiho Pharmaceutical Co Ltd, and others

• Key Chondrosarcoma Therapies: INBRX-109, TIBSOVO (ivosidenib), and others

• Chondrosarcoma Therapeutic Assessment: Chondrosarcoma current marketed and Chondrosarcoma emerging therapies

• Chondrosarcoma Market Dynamics: Chondrosarcoma market drivers and Chondrosarcoma market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Chondrosarcoma Unmet Needs, KOL’s views, Analyst’s views, Chondrosarcoma Market Access and Reimbursement

To get detailed insights on the scope of our chondrosarcoma market report

Table of Contents

1. Report Introduction

2. Executive Summary

3. SWOT analysis

4. Chondrosarcoma Patient Share (%) Overview at a Glance

5. Chondrosarcoma Market Overview at a Glance

6. Chondrosarcoma Disease Background and Overview

7. Chondrosarcoma Epidemiology and Patient Population

8. Country-Specific Patient Population of Chondrosarcoma

9. Chondrosarcoma Current Treatment and Medical Practices

10. Unmet Needs

11. Chondrosarcoma Emerging Therapies

12. Chondrosarcoma Market Outlook

13. Country-Wise Chondrosarcoma Market Analysis (2020–2034)

14. Market Access and Reimbursement of Therapies

15. Market drivers

16. Market barriers

17. Appendix

18. Chondrosarcoma Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

Related Reports:

Chondrosarcoma Pipeline Insights, DelveInsight

“Chondrosarcoma Pipeline Insight, 2024” report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Chondrosarcoma market. A detailed picture of the Chondrosarcoma pipeline landscape is provided, which includes the disease overview and Chondrosarcoma treatment guidelines.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/